You are here

A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Daiyukai First Hospital
Ichinomiya, Aichi, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Intra-abdominal Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16-79 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 16 years of age or older.

- Diagnosed with intra-abdominal infections or pelvic inflammatory diseases.

- Can be obtained a specimen for bacteriological efficacy assessment.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known or suspected hypersensitivity, intolerance or contraindication to Metronidazole,
Ceftriaxone sodium, or other cephem antibiotics.

- Severe renal dysfunction (creatinine clearance Cockcroft-Gault calculation formula.

- Hepatic dysfunction (AST, ALT, total bilirubin > 3 times upper limit of normal range
values).

- Severe underlying disease; patients in which drug clinical evaluation is difficult
because of confounding diseases.

NCT01473836
Pfizer
Completed
A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now